Bristol Myers' lung disease drug meets main goal in late-stage trial

2

Oct 12 (Reuters) – Bristol Myers Squibb said on Monday its experimental drug met the main goal of a late-stage trial in patients with idiopathic pulmonary fibrosis, a serious lung-scarring disease. (

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)